all ( 24 results found)
DHPC - Risk of secondary malignancy of T-cell origin in CD19- or BCMA-directed CAR T-cell therapies
DHPC enzalutamide test interference leading to falsely elevated digoxin plasma levels
Direct healthcare professional communication (DHPC) - Evrysdi 0.75 mg/mL powder for oral solution (risdiplam)
Dzuveo cover letter
Dzuveo DHCP letter
EpiPen® Healthcare Professional Letter
EpiPen® Healthcare Professional Letter
Finasteride, dutasteride – New measures to minimise the risk of suicidal ideation
Fluoroquinolones DHPC_HPRA_FINAL vs2 30-05-23
IE Adcortyl Discontinuation Letter June 2025
Infanrix Hexa - DHPC
Mubucho HCP cover letter
Mubucho HCP Cover Letter
Mubucho HCP Cover Letter
Mubucho HCP Cover letter
Mubucho HCP cover letter
Mubucho HCP letter
Risperidone 1mg per ml OS-Risk of medication errors leading to accidental overdoses in children and adolescents
Topiramate: New restrictions to prevent exposure during pregnancy
Topiramate: New restrictions to prevent exposure during pregnancy
Topiramate: New restrictions to prevent exposure during pregnancy
Topiramate: New restrictions to prevent exposure during pregnancy
Topiramate: New restrictions to prevent exposure during pregnancy
Topiramate: New restrictions to prevent exposure during pregnancy
Veoza - 45mg film-coated tablets_DHPC January 2025